Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies

被引:700
作者
Dzau, VJ [1 ]
Braun-Dullaeus, RC
Sedding, DG
机构
[1] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Giessen, Dept Med, Giessen, Germany
关键词
D O I
10.1038/nm1102-1249
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention as well as to the formation of the fibrous cap that provides stability to the plaque. The VSMC can undergo a proliferative response that underlies the development of in stent restenosis, bypass graft occlusion and transplant vasculopathy Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of antiproliferative therapy for in-stent restenosis, bypass graft failure and other vascular proliferative disorders.
引用
收藏
页码:1249 / 1256
页数:8
相关论文
共 83 条
  • [1] Axel DI, 1997, CIRCULATION, V96, P636
  • [2] INHIBITORY EFFECTS OF ANTISENSE OLIGODEOXYNUCLEOTIDES TARGETING C-MYC MESSENGER-RNA ON SMOOTH-MUSCLE CELL-PROLIFERATION AND MIGRATION
    BIRO, S
    FU, YM
    YU, ZX
    EPSTEIN, SE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) : 654 - 658
  • [3] A novel role for the cyclin-dependent kinase inhibitor p27Kip1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy
    Braun-Dullaeus, RC
    Mann, MJ
    Ziegler, A
    von der Leyen, HE
    Dzau, VJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (06) : 815 - 823
  • [4] Cell cycle progression - New therapeutic target for vascular proliferative disease
    Braun-Dullaeus, RC
    Mann, MJ
    Dzau, VJ
    [J]. CIRCULATION, 1998, 98 (01) : 82 - 89
  • [5] Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin
    Braun-Dullaeus, RC
    Mann, MJ
    Seay, U
    Zhang, LN
    von der Leyen, HE
    Morris, RE
    Dzau, VJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (07) : 1152 - 1158
  • [6] CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation
    Brooks, EE
    Gray, NS
    Joly, A
    Kerwar, SS
    Lum, R
    Mackman, RL
    Norman, TC
    Rosete, J
    Rowe, M
    Schow, SR
    Schultz, PG
    Wang, XB
    Wick, MM
    Shiffman, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (46) : 29207 - 29211
  • [7] Campbell JH, 2001, ANN NY ACAD SCI, V947, P18
  • [8] EXISTENCE OF A SOLUTION IN AN AGE-DEPENDENT TRANSPORT-DIFFUSION PDE - A MODEL OF SETTLER
    CHANCELIER, JP
    DELARA, MC
    PACARD, F
    [J]. MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCES, 1995, 5 (03) : 267 - 278
  • [9] Downregulation of cyclin-dependent kinase 2 activity and cyclin a promoter activity in vascular smooth muscle cells by p27(KIP1), inhibitor of neointima formation in the rat carotid artery
    Chen, DH
    Krasinski, K
    Chen, DF
    Sylvester, A
    Chen, J
    Nisen, PD
    Andres, V
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) : 2334 - 2341
  • [10] Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro
    DeRuiter, MC
    Poelmann, RE
    VanMunsteren, JC
    Mironov, V
    Markwald, RR
    GittenbergerdeGroot, AC
    [J]. CIRCULATION RESEARCH, 1997, 80 (04) : 444 - 451